Lazard Asset Management
MRVI icon

Lazard Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Lazard Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.4M Sell
847,799
-170,919
-17% -$579K ﹤0.01% 812
2025
Q4 		$3.31M Sell
1,018,718
-521,508
-34% -$1.76M 0.01% 683
2025
Q3 		$4.42M Buy
1,540,226
+89,805
+6% +$229K 0.01% 611
2025
Q2 		$3.5M Buy
1,450,421
+44,128
+3% +$92.7K ﹤0.01% 839
2025
Q1 		$3.11M Sell
1,406,293
-41,421
-3% -$164K ﹤0.01% 829
2024
Q4 		$7.89M Buy
1,447,714
+127,672
+10% +$821K 0.01% 526
2024
Q3 		$11M Buy
1,320,042
+169,468
+15% +$1.46M 0.01% 447
2024
Q2 		$8.24M Buy
1,150,574
+785,415
+215% +$6.78M 0.01% 553
2024
Q1 		$3.17M Buy
365,159
+359,411
+6,253% +$2.43M ﹤0.01% 761
2023
Q4 		$37K Buy
5,748
+1,934
+51% +$12.5K ﹤0.01% 1971
2023
Q3 		$37K Buy
3,814
+159
+4% +$1.75K ﹤0.01% 1942
2023
Q2 		$44K Sell
3,655
-5,695
-61% -$76.9K ﹤0.01% 1874
2023
Q1 		$130K Buy
9,350
+6,027
+181% +$86.6K ﹤0.01% 1433
2022
Q4 		$47K Buy
3,323
+3,283
+8,208% +$51.7K ﹤0.01% 1849
2022
Q3 		$1K Sell
40
-61
-60% -$1.53K ﹤0.01% 2259
2022
Q2 		$2K Hold
101
– – ﹤0.01% 2295
2022
Q1 		$3K Sell
101
-211
-68% -$7.07K ﹤0.01% 2220
2021
Q4 		$13K Sell
312
-351,638
-100% -$14.2M ﹤0.01% 2103
2021
Q3 		$17.3M Sell
351,950
-1,366,771
-80% -$66.7M 0.02% 517
2021
Q2 		$71.7M Sell
1,718,721
-1,642,546
-49% -$63.7M 0.08% 215
2021
Q1 		$120M Sell
3,361,267
-54,030
-2% -$1.79M 0.15% 127
2020
Q4 		$95.8M Buy
+3,415,297
New +$95.1M 0.12% 153

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management's MRVI Position: Q1 2026 in Review

Lazard Asset Management reduced its Maravai LifeSciences (MRVI) stake by 17% in Q1 2026, selling an estimated $579K and leaving 847,799 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #812.

Lazard Asset Management first reported a position in MRVI in Q4 2020 and has held it in 22 quarters since. The position peaked at $120M in Q1 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Lazard Asset Management held 847,799 shares of Maravai LifeSciences worth $2.4M as of Q1 2026.
  • Lazard Asset Management sold 170,919 Maravai LifeSciences shares in Q1 2026, an estimated $579K.
  • Maravai LifeSciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #812 holding.
  • Lazard Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 22 quarters since.
  • Lazard Asset Management's Maravai LifeSciences position peaked at $120M in Q1 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.